Rapid Diagnostics Market Report 2026

The rapid diagnostics market size has grown rapidly in recent years. It will grow from $36.08 billion in 2025 to $40.66 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing demand for faster clinical diagnostics, expansion of decentralized healthcare settings, rising prevalence of chronic and infectious diseases, improved accessibility of diagnostic tools, growth of outpatient diagnostic services.

The rapid diagnostics market size is expected to see rapid growth in the next few years. It will grow to $64.79 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing investments in molecular diagnostics, rising adoption of connected diagnostic devices, expansion of home-based testing solutions, growing focus on personalized diagnostics, increasing use of data-driven clinical workflows. Major trends in the forecast period include increasing use of point-of-care diagnostic platforms, rising adoption of molecular rapid testing, growing integration of digital result interpretation, expansion of portable diagnostic instruments, enhanced focus on early clinical decision support.

The rising prevalence of infectious diseases is expected to drive the growth of the rapid diagnostics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly from one individual to another. The increasing prevalence of infectious diseases is fueled by higher global travel, which accelerates transmission and raises infection rates. Rapid diagnostics support infectious disease management by enabling quick and accurate pathogen identification, facilitating timely treatment, reducing transmission, and improving patient outcomes. For instance, in May 2025, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, global SARS-CoV-2 (the virus causing COVID-19) activity has been rising since mid-February 2025, based on data from sentinel sites, with the test positivity rate reaching 11%, a level last observed in July 2024. Therefore, the increasing prevalence of infectious diseases is driving the rapid diagnostics market.

Major companies in the rapid diagnostics market are focusing on technological advancements and innovations, such as rapid diagnostic testing tools, to enhance accuracy, shorten turnaround times, and improve patient outcomes in point-of-care settings. Rapid diagnostic testing tools are medical devices that quickly detect the presence of specific diseases or conditions, typically providing results within minutes at the point of care. For instance, in May 2025, SEKISUI Diagnostics, a US-based medical diagnostics manufacturer, launched the OSOM RSV Test, a rapid diagnostic tool for detecting respiratory syncytial virus (RSV). This test is designed for professional healthcare settings and delivers results in just 15 minutes. It uses a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen from anterior nasal swab specimens collected from symptomatic patients. The quick turnaround time enables timely and effective clinical decision-making.

In June 2023, Avacta Group, a UK-based biotechnology company, acquired Coris Bioconcept SRL for an undisclosed amount. Through this acquisition, Avacta Group aims to expand its diagnostics portfolio and strengthen capabilities in rapid testing technologies for infectious diseases and antimicrobial resistance. Coris Bioconcept SRL is a Belgium-based biotechnology company that develops, manufactures, and markets rapid diagnostic tests.

Major companies operating in the rapid diagnostics market are Johnson And Johnson Services Inc, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Hologic Inc, bioMerieux SA, QuidelOrtho Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Cepheid Inc, OraSure Technologies Inc, Nova Biomedical Corporation, Fujirebio Holdings Inc, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Abingdon Health plc, Abionic SA, LumiraDx Ltd.

North America was the largest region in the rapid diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rapid diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rapid diagnostics market by increasing costs of imported diagnostic instruments, reagents, biosensors, microfluidic components, and electronic modules. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported diagnostic platforms, while Asia-Pacific faces increased production costs for export-focused manufacturing. These tariffs are elevating equipment prices and delaying technology upgrades. However, they are also supporting regional manufacturing, local assembly of diagnostic instruments, and development of cost-optimized rapid diagnostic solutions.

The rapid diagnostics market research report is one of a series of new reports that provides rapid diagnostics market statistics, including rapid diagnostics industry global market size, regional shares, competitors with a rapid diagnostics market share, detailed rapid diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rapid diagnostics industry. This rapid diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rapid diagnostics refer to medical tests designed to quickly detect the presence or absence of specific pathogens, conditions, or biomarkers, typically delivering results within minutes to a few hours. These tests are commonly used at the point of care, enabling timely clinical decisions, early treatment, and improved patient outcomes.

The primary product types of rapid diagnostics include kits, reagents, instruments, and other product types. Kits are pre-assembled diagnostic tools that include all essential components, such as reagents, assay devices, and instructions, for performing specific tests quickly and accurately. Platforms include immunoassays, molecular detection, and other rapid diagnostic technologies, applied in areas such as blood glucose testing, infectious disease testing, cardio-metabolic testing, pregnancy and fertility testing, fecal occult blood testing, coagulation testing, and toxicology testing. Rapid diagnostics are distributed through channels such as hospital pharmacies, brick-and-mortar stores, e-commerce platforms, and others, serving end users including diagnostic centers, homecare settings, hospital pharmacies, and additional end users.

The rapid diagnostics market includes revenues earned by providing services such as quick and accurate testing for diseases, infections, and medical conditions using point-of-care diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The rapid diagnostics market consists of sales of quick diagnostic test kits and devices used for the rapid detection of diseases and medical conditions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.